Predicting the Risk of Stroke with the Help of an Artificial Intelligence System
ODMachine (ODM) is expanding its clinical trials and has signed an agreement to conduct a clinical trial at the Kaplan Medical Center. This agreement is in addition to clinical trial agreements previously signed with Maccabi Healthcare Services and the Poriya Medical Center.
A prospective clinical trial has now begun, under the direction of Dr. Sagi Tshori, Chairman of the Kaplan Hospital Research Authority, regarding ODM’s “Optima Stroke” product, that predicts the risk of having a stroke using a self- learning artificial intelligence (AI) platform.
Optima Stroke will reduce stroke prevalence and save lives through preventive medicine. The product uses powerful AI and imaging processing technologies to assess the risk of having a stroke due to carotid artery disease (calcification in the carotid arteries), which is the main medical factor that significantly increases the risk of strokes. Stroke prediction and prevention has a critical impact on a patient’s future quality of life. In addition, preventing incidents will reduce the immense economic burden to healthcare systems by avoiding the costs of hospitalization, surgery, rehabilitation, nursing, and the treatment of related complications.
One of the unique strengths of the ODM platform is its ability to cross-reference information from different medical fields that are seemingly unrelated and, using advanced algorithms that integrate the information within diverse technologies, to obtain highly significant results and reach new pertinent findings.
Dr. Gil Pogozelich, the company’s chairman, said that the enrollment of ODM’s highly proficient team, including Prof. Morris Mosseri, Dr. Moshe Amitay, Dr. Zohar Barnett-Itzhaki and Dr. Yoav Smith, to develop the product, will create a strong competitive advantage. “We attach great importance to expanding our clinical trials, and to collaborating with the excellent medical research personnel working in the Israeli hospitals.
There are many economic considerations for early detection and prevention, but our mission is to enable better medicine by utilizing existing data in order for patients to continue to live healthy lives without any of the disabilities that could arise once the symptoms of stroke are evident.”